GPBAR1 and metabolic disease: Bile acids can act on Takeda G-protein-coupled receptor 5 (TGR5) and farnesoid X (FXR), and the dual activation of TGR5 and FXR can effectively promote lipid and glucose metabolism and prevent the emergence of various metabolic diseases [90,91,92].